<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">systhiper</journal-id><journal-title-group><journal-title xml:lang="ru">Системные гипертензии</journal-title><trans-title-group xml:lang="en"><trans-title>Systemic Hypertension</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2075-082X</issn><issn pub-type="epub">2542-2189</issn><publisher><publisher-name>LLC «ИнтерМедсервис»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">systhiper-763</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ARTICLES</subject></subj-group></article-categories><title-group><article-title>b-Адреноблокаторы в терапии артериальной гипертензии: на пути к разумному компромиссу</article-title><trans-title-group xml:lang="en"><trans-title></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Перепеч</surname><given-names>Н. Б.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шурыгина</surname><given-names>В. Д.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>Научно-клинический и образовательный центр «Кардиология» Санкт-Петербургского государственного университета</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>09</day><month>02</month><year>2023</year></pub-date><volume>9</volume><issue>4</issue><fpage>22</fpage><lpage>27</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Перепеч Н.Б., Шурыгина В.Д., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Перепеч Н.Б., Шурыгина В.Д.</copyright-holder><copyright-holder xml:lang="en">Перепеч Н.Б., Шурыгина В.Д.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.syst-hypertension.ru/jour/article/view/763">https://www.syst-hypertension.ru/jour/article/view/763</self-uri></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Диагностика и лечение артериальной гипертензии. Российские рекомендации (4-й пересмотр). Системные гипертензии. 2010; 3: 5-26.</mixed-citation><mixed-citation xml:lang="en">Диагностика и лечение артериальной гипертензии. Российские рекомендации (4-й пересмотр). Системные гипертензии. 2010; 3: 5-26.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Hypertension: clinical management of primary hypertension in adults. NICE clinical guideline 127, 2011; guidance.nice.org.uk/CG 127.</mixed-citation><mixed-citation xml:lang="en">Hypertension: clinical management of primary hypertension in adults. NICE clinical guideline 127, 2011; guidance.nice.org.uk/CG 127.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27 (11): 2121-58.</mixed-citation><mixed-citation xml:lang="en">Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27 (11): 2121-58.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Dahlof B et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required in the ASCOT-BPLA: a multicenter randomized controlled trial. Lancet 2005; 366: 895-906.</mixed-citation><mixed-citation xml:lang="en">Dahlof B et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required in the ASCOT-BPLA: a multicenter randomized controlled trial. Lancet 2005; 366: 895-906.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Carlberg B, Samuelsson O, Lindholm LN. Atenolol in hypertension: is it a wise choise? Lancet 2004; 364 (9446): 1684-9.</mixed-citation><mixed-citation xml:lang="en">Carlberg B, Samuelsson O, Lindholm LN. Atenolol in hypertension: is it a wise choise? Lancet 2004; 364 (9446): 1684-9.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-53.</mixed-citation><mixed-citation xml:lang="en">Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-53.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">The CAFE Investigators. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-25.</mixed-citation><mixed-citation xml:lang="en">The CAFE Investigators. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-25.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Mancia G, De Baker G, Dominiczak A et al. ESH-ESC Practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the management of arterial hypertension. J Hypertens 2007; 25 (9): 1751-62.</mixed-citation><mixed-citation xml:lang="en">Mancia G, De Baker G, Dominiczak A et al. ESH-ESC Practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the management of arterial hypertension. J Hypertens 2007; 25 (9): 1751-62.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Elliott W, Meyer P. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201-7.</mixed-citation><mixed-citation xml:lang="en">Elliott W, Meyer P. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201-7.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">De Caterina AR, Leone AM. The role of beta-blockers as first-line therapy in hypertension. Curr Atheroscler Rep 2011; 13 (2): 147-53.</mixed-citation><mixed-citation xml:lang="en">De Caterina AR, Leone AM. The role of beta-blockers as first-line therapy in hypertension. Curr Atheroscler Rep 2011; 13 (2): 147-53.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Wiysonge CS, Bradley HA, Volmink J et al. Cochrane Database Syst Rev 2012; 8: CD002003.</mixed-citation><mixed-citation xml:lang="en">Wiysonge CS, Bradley HA, Volmink J et al. Cochrane Database Syst Rev 2012; 8: CD002003.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Stoschitzky K. Individual beta-blockers for individual patients. E-journal ESC Council Cardiology practice 2008; 6 (19).</mixed-citation><mixed-citation xml:lang="en">Stoschitzky K. Individual beta-blockers for individual patients. E-journal ESC Council Cardiology practice 2008; 6 (19).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br Med J 1985; 291 (6488): 97-104.</mixed-citation><mixed-citation xml:lang="en">MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br Med J 1985; 291 (6488): 97-104.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Прогнозирование и профилактика кардиальных осложнений внесердечных хирургических вмешательств. Национальные рекомендации. Кардиоваскулярная терапия и профилактика. 2011; Прил. 3: 10 (6).</mixed-citation><mixed-citation xml:lang="en">Прогнозирование и профилактика кардиальных осложнений внесердечных хирургических вмешательств. Национальные рекомендации. Кардиоваскулярная терапия и профилактика. 2011; Прил. 3: 10 (6).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Leonetti G, Egan CG. Use of carvedilol in hypertension: an update. Vasc Health Risk Manag 2012; 8: 307-22.</mixed-citation><mixed-citation xml:lang="en">Leonetti G, Egan CG. Use of carvedilol in hypertension: an update. Vasc Health Risk Manag 2012; 8: 307-22.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Bangalore S, Messerli FH. Beta-blockers in hypertension to use or not to use? Kardiovaskulare Medizine 2008; 11: 117-23.</mixed-citation><mixed-citation xml:lang="en">Bangalore S, Messerli FH. Beta-blockers in hypertension to use or not to use? Kardiovaskulare Medizine 2008; 11: 117-23.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Клинические рекомендации «Диагностика и лечение артериальной гипертензии у беременных». ВНОК-РМОАГ. 2010; http://www.ncagip.ru/news/1438.html</mixed-citation><mixed-citation xml:lang="en">Клинические рекомендации «Диагностика и лечение артериальной гипертензии у беременных». ВНОК-РМОАГ. 2010; http://www.ncagip.ru/news/1438.html</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Aronow WS. Current role of beta-blockers in the treatment of hypertension. Expert Opin Pharmacother 2010; 11: 2599-607.</mixed-citation><mixed-citation xml:lang="en">Aronow WS. Current role of beta-blockers in the treatment of hypertension. Expert Opin Pharmacother 2010; 11: 2599-607.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Yusuf S, Pais P, Afzal R et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009; 373 (9672): 1341-51.</mixed-citation><mixed-citation xml:lang="en">Yusuf S, Pais P, Afzal R et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009; 373 (9672): 1341-51.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Rothwell PM, Howard SC, Dolan E et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375 (9718): 895-905.</mixed-citation><mixed-citation xml:lang="en">Rothwell PM, Howard SC, Dolan E et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375 (9718): 895-905.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Rothwell PM. Does blood pressure variability modulate cardiovascular risk? Curr Hypertens Rep 2011; 13 (3): 177-86.</mixed-citation><mixed-citation xml:lang="en">Rothwell PM. Does blood pressure variability modulate cardiovascular risk? Curr Hypertens Rep 2011; 13 (3): 177-86.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Кобалава Ж.Д., Гудков К.М. Метопролол CR/XL: усовершенствованная форма эталонного бета-блокатора. Кардиология. 2003; 9: 91-100.</mixed-citation><mixed-citation xml:lang="en">Кобалава Ж.Д., Гудков К.М. Метопролол CR/XL: усовершенствованная форма эталонного бета-блокатора. Кардиология. 2003; 9: 91-100.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Hedblad B, Wikstrand J, Janzon L. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness main result from the β-Blockers Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103: 1721-6.</mixed-citation><mixed-citation xml:lang="en">Hedblad B, Wikstrand J, Janzon L. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness main result from the β-Blockers Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103: 1721-6.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Wiklund O, Hulthe J, Wikstrand J. Effect of controlled releaize/extended releaize metoprolol on carotid intima-media thickness in patients with hypercholesterolemia a 3-year randomized study. Stroke 2002; 33: 572-7.</mixed-citation><mixed-citation xml:lang="en">Wiklund O, Hulthe J, Wikstrand J. Effect of controlled releaize/extended releaize metoprolol on carotid intima-media thickness in patients with hypercholesterolemia a 3-year randomized study. Stroke 2002; 33: 572-7.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Shiri R, Koskimäki J, Häkkinen J et al. Cardiovascular Drug Use and the Incidence of Erectile Dysfunction. Int J Impot Res 2007; 19 (2): 208-12.</mixed-citation><mixed-citation xml:lang="en">Shiri R, Koskimäki J, Häkkinen J et al. Cardiovascular Drug Use and the Incidence of Erectile Dysfunction. Int J Impot Res 2007; 19 (2): 208-12.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
